Medical oncologists provide comprehensive insights on treatment practices for patients with extended-stage small cell lung cancer.
Frontline Tislelizumab Combo Improves Long-Term Survival in ES-SCLC
Findings from the RATIONALE-312 trial support tislelizumab plus chemotherapy as a frontline treatment option in extensive-stage small cell lung cancer.
Leveraging Biology to Advance the Small Cell Lung Cancer Treatment Paradigm
“Paradigm-changing events” are occurring across the small cell lung cancer field in real time, according to Anne Chiang, MD, PhD.
Tarlatamab Improves Survival vs Chemotherapy in Second-Line SCLC Subgroups
Data from DeLLphi-304 support the use of tarlatamab as a standard of care for all patients with second-line small cell lung cancer.
Practice-Changing Lung Cancer Data From the 2025 ASCO Annual Meeting
Stephen Liu, MD; and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.
Progastrin-Releasing Peptide Levels Correlate With OS and PFS in LS-SCLC
Those with limited-stage small cell lung cancer who had elevated ProGRP levels at baseline had worse OS and PFS outcomes vs those with normalized levels.
Unraveling The Benefits of Twice-Daily Chemoradiotherapy in LS-SCLC
Twice-daily radiotherapy prolongs survival vs once-daily radiation among those with LS-SCLC, even with the incorporation of immunotherapy.